scholarly journals Improved queue-size scaling for input-queued switches via graph factorization

2020 ◽  
Vol 52 (3) ◽  
pp. 798-824
Author(s):  
Jiaming Xu ◽  
Yuan Zhong

AbstractThis paper studies the scaling of the expected total queue size in an $n\times n$ input-queued switch, as a function of both the load $\rho$ and the system scale n. We provide a new class of scheduling policies under which the expected total queue size scales as $O\big( n(1-\rho)^{-4/3} \log \big(\!\max\big\{\frac{1}{1-\rho}, n\big\}\big)\big)$, over all n and $\rho<1$, when the arrival rates are uniform. This improves on the best previously known scalings in two regimes: $O\big(n^{1.5}(1-\rho)^{-1} \log \frac{1}{1-\rho}\big)$ when $\Omega\big(n^{-1.5}\big) \le 1-\rho \le O\big(n^{-1}\big)$ and $O\big(\frac{n\log n}{(1-\rho)^2}\big)$ when $1-\rho \geq \Omega(n^{-1})$. A key ingredient in our method is a tight characterization of the largest k-factor of a random bipartite multigraph, which may be of independent interest.

2020 ◽  
Vol 20 (7) ◽  
pp. 490-500 ◽  
Author(s):  
Justin S. Becker ◽  
Amir T. Fathi

The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has illuminated subclasses of the disease, with distinct driver mutations, that might be responsive to targeted therapies. Approximately 15-23% of AML genomes harbor mutations in one of two isoforms of isocitrate dehydrogenase (IDH1 or IDH2). These enzymes are constitutive mediators of basic cellular metabolism, but their mutated forms in cancer synthesize an abnormal metabolite, 2- hydroxyglutarate, that in turn acts as a competitive inhibitor of multiple gene regulatory enzymes. As a result, leukemic IDH mutations cause changes in genome structure and gene activity, culminating in an arrest of normal myeloid differentiation. These discoveries have motivated the development of a new class of selective small molecules with the ability to inhibit the mutant IDH enzymes while sparing normal cellular metabolism. These agents have shown promising anti-leukemic activity in animal models and early clinical trials, and are now entering Phase 3 study. This review will focus on the growing preclinical and clinical data evaluating IDH inhibitors for the treatment of IDH-mutated AML. These data suggest that inducing cellular differentiation is central to the mechanism of clinical efficacy for IDH inhibitors, while also mediating toxicity for patients who experience IDH Differentiation Syndrome. Ongoing trials are studying the efficacy of IDH inhibitors in combination with other AML therapies, both to evaluate potential synergistic combinations as well as to identify the appropriate place for IDH inhibitors within existing standard-of-care regimens.


2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Lyudmila P. Trenozhnikova ◽  
Almagul K. Khasenova ◽  
Assya S. Balgimbaeva ◽  
Galina B. Fedorova ◽  
Genrikh S. Katrukha ◽  
...  

We describe the actinomycete strain IMV-70 isolated from the soils of Kazakhstan, which produces potent antibiotics with high levels of antibacterial activity. After the research of its morphological, chemotaxonomic, and cultural characteristics, the strain with potential to be developed further as a novel class of antibiotics with chemotherapeutics potential was identified asStreptomycessp. IMV-70. In the process of fermentation, the strainStreptomycesspp. IMV-70 produces the antibiotic no. 70, which was isolated from the culture broth by extraction with organic solvents. Antibiotic compound no. 70 was purified and separated into individual components by HPLC, TLC, and column chromatography methods. The main component of the compound is the antibiotic 70-A, which was found to be identical to the peptolide etamycin A. Two other antibiotics 70-B and 70-C have never been described and therefore are new antibiotics. The physical-chemical and biological characteristics of these preparations were described and further researched. Determination of the optimal growth conditions to cultivate actinomycete-producer strain IMV-70 and development of methods to isolate, purify, and accumulate preparations of the new antibiotic no. 70 enable us to research further the potential of this new class of antibiotics.


1998 ◽  
Vol 07 (04) ◽  
pp. 503-508 ◽  
Author(s):  
ANDRZEJ SZCZEPAŃSKI

We shall present a new class of examples of high dimensional knot groups. All of them are HNN extensions of the Fibonacci groups. We give also some characterization of these groups.


Virology ◽  
1975 ◽  
Vol 64 (1) ◽  
pp. 144-152 ◽  
Author(s):  
Richard E. Depew ◽  
Thomas J. Snopek ◽  
Nicholas R. Cozzarelli
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document